Frank van Landeghem

ORCID: 0000-0002-9404-7031
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glioma Diagnosis and Treatment
  • Chromatin Remodeling and Cancer
  • Neurofibromatosis and Schwannoma Cases
  • Neuroscience and Neuropharmacology Research
  • Photoacoustic and Ultrasonic Imaging
  • Neurogenetic and Muscular Disorders Research
  • Meningioma and schwannoma management
  • Hedgehog Signaling Pathway Studies
  • Cancer, Hypoxia, and Metabolism
  • Cancer Genomics and Diagnostics
  • Brain Metastases and Treatment
  • interferon and immune responses
  • Thermography and Photoacoustic Techniques
  • Muscle Physiology and Disorders
  • Ferroptosis and cancer prognosis
  • Neuroblastoma Research and Treatments
  • Amino Acid Enzymes and Metabolism
  • RNA modifications and cancer
  • Genetics and Neurodevelopmental Disorders
  • Bone Tumor Diagnosis and Treatments
  • Pituitary Gland Disorders and Treatments
  • Congenital heart defects research
  • Traumatic Brain Injury and Neurovascular Disturbances
  • Amyotrophic Lateral Sclerosis Research
  • Caveolin-1 and cellular processes

University of Alberta
2014-2024

Women and Children’s Health Research Institute
2018-2024

University of Alberta Hospital
2017-2024

Alberta Hospital Edmonton
2017-2024

Stollery Children's Hospital
2019-2024

Cleveland Clinic
2024

University of Bonn
2008-2023

Health Sciences Centre
2020-2021

Princess Margaret Cancer Centre
2016

Hospital for Sick Children
2016

Infant gliomas have paradoxical clinical behavior compared to those in children and adults: low-grade tumors a higher mortality rate, while high-grade better outcome. However, we little understanding of their biology therefore cannot explain this nor what constitutes optimal management. Here report comprehensive genetic analysis an international cohort clinically annotated infant gliomas, revealing 3 subgroups. Group 1 arise the cerebral hemispheres harbor alterations receptor tyrosine...

10.1038/s41467-019-12187-5 article EN cc-by Nature Communications 2019-09-25
Vijay Ramaswamy Thomas Hielscher Stephen C. Mack Álvaro Lassaletta Tong Lin and 95 more Kristian W. Pajtler David Jones Betty Luu Florence M.G. Cavalli Kenneth Aldape Marc Remke Martin Mynarek Stefan Rutkowski Sridharan Gururangan Roger E. McLendon Eric Lipp Christopher Dunham Juliette Hukin David D. Eisenstat Dorcas Fulton Frank van Landeghem Mariarita Santi Marie‐Lise C. van Veelen Erwin G. Van Meir Satoru Osuka Xing Fan Karin M. Muraszko Daniela Pretti da Cunha Tirapelli Sueli Mieko Oba‐Shinjo Suely Kazue Nagahashi Marie Carlos Gilberto Carlotti Ji Yeoun Lee Amulya A. Nageswara Rao Caterina Giannini Cláudia C. Faria Sofia Nunes Jaume Mora Ronald L. Hamilton Péter Hauser Nada Jabado Kevin Petrecca Shin Jung Luca Massimi Massimo Zollo Giuseppe Cinalli László Bognár Álmos Klekner Tibor Hortobágyi Sarah Leary Ralph Ermoian James M. Olson Jeffrey R. Leonard Corrine Gardner Wiesława Grajkowska Lola B. Chambless Jason Cain Charles G. Eberhart Sama Ahsan Maura Massimino Felice Giangaspero Francesca Romana Buttarelli Roger J. Packer Lyndsey Emery William H. Yong Horacio Soto Linda M. Liau Richard G. Everson Andrew J. Grossbach Tarek Shalaby Michael Grotzer Matthias A. Karajannis David Zagzag Helen Wheeler Katja von Hoff Marta M. Alonso T. Tuñón Ulrich Schüller Karel Zitterbart Jaroslav Štěrba Jennifer A. Chan Miguel A. Guzmán Samer K. Elbabaa Howard Colman Girish Dhall Paul G. Fisher Maryam Fouladi Amar Gajjar Stewart Goldman Eugene Hwang Marcel Kool Harshad Ladha Elizabeth Vera‐Bolanos Khalida Wani Frank S. Lieberman Tom Mikkelsen Antonio Omuro Ian F. Pollack Michael D. Prados H. Ian Robins Riccardo Soffietti

Posterior fossa ependymoma comprises two distinct molecular variants termed EPN_PFA and EPN_PFB that have a biology natural history. The therapeutic value of cytoreductive surgery radiation therapy for posterior after accounting subgroup is not known.Four independent nonoverlapping retrospective cohorts ependymomas (n = 820) were profiled using genome-wide methylation arrays. Risk stratification models designed based on known clinical newly described biomarkers identified by multivariable...

10.1200/jco.2015.65.7825 article EN Journal of Clinical Oncology 2016-06-07

The occurrence of neurological symptoms and developmental delay in patients affected by congenital hypothyroidism (CH) has been attributed to the lack thyroid hormone developing CNS. Accordingly, after introduction neonatal screening programs for CH, which allowed early adequate treatment, an almost normal outcome most CH could be achieved. However, a few did not reach this favorable despite treatment. Here we describe five with variable degrees who suffered from choreoathetosis, muscular...

10.1172/jci14341 article EN Journal of Clinical Investigation 2002-02-15

The occurrence of neurological symptoms and developmental delay in patients affected by congenital hypothyroidism (CH) has been attributed to the lack thyroid hormone developing CNS. Accordingly, after introduction neonatal screening programs for CH, which allowed early adequate treatment, an almost normal outcome most CH could be achieved. However, a few did not reach this favorable despite treatment. Here we describe five with variable degrees who suffered from choreoathetosis, muscular...

10.1172/jci0214341 article EN Journal of Clinical Investigation 2002-02-15

PURPOSE Children with pediatric gliomas harboring a BRAF V600E mutation have poor outcomes current chemoradiotherapy strategies. Our aim was to study the role of targeted inhibition in these tumors. PATIENTS AND METHODS We collected clinical, imaging, molecular, and outcome information from patients V600E–mutated glioma treated across 29 centers multiple countries. RESULTS Sixty-seven were (pediatric low-grade [PLGGs], n = 56; high-grade [PHGGs], 11) for up 5.6 years. Objective responses...

10.1200/po.19.00298 article EN JCO Precision Oncology 2020-05-20
Christopher S. Chen Edward Franklin Y Li Nelly Joseph‐Mathurin Anthony S. Burns and 95 more G Wang Tammie L.S. Benzinger Randall J. Bateman Richard J. Perrin Sonal Agrawal Lei Yu Lisa L. Barnes David A. Bennett Julie A. Schneider Martha Clare Morris Genevieve Stein-O’Brien Ryan G. Palaganas Elaine C. Meyer Javier Redding‐Ochoa Olga Pletnikova H Guo William R. Bell Juan C. Troncoso Richard L. Huganir Adam Seth Levine Julie Bennett Chantel Cacciotti Samantha J DeMarsh Adriana Rodrigues Fonseca Guerreiro Stuecklin Jordan R. Hansford Louise E. Ludlow M. Aaron MacNeil Jean M. Mulcahy Levy Parag G. Patil Ashley Plant Beverley Wilson Fleming Richard Graham Joseline Haizel‐Cobbina Yoshiko Nakano Salmo Raskin Christopher Dunham Craig Erker C Li Mona Nasrallah E. C. Nelson Mohit Rana M Santi-Vicini Frank van Landeghem J Vel Azquez Vega Richard Yuditskiy Michael C. Dewan Uri Tabori Cynthia Hawkins Kenneth Aldape D. Hoang Elizabeth P. Shulman Emma M. Campagnolo Zied Abdullaev H Lalchungnunga Om V. Singh Eric A. Stone Eytan Ruppin Y. Zhu Darin D. Carabenciov D Johnson Jorge Trejo‐Lopez Andrew Nguyen A Raghunathan G Lanzino Cristiane M. Ida Zepeda Mendoza Giannini Mayo Professor Nikhil Patel Lynn M. Bekris Shane Formica Debby W. Tsuang Cyrus P. Zabetian Irene Litvan Jori Fleisher Sarah Berman David J. Irwin Andrea Bozoki Carol F. Lippa F. DiFillipo Lorna M. Lopez Douglas Galasko James B. Leverenz Marvin J. Miller C.M. Ma G Dong Suresh R. Naik Gannon A. McDonough Shaokuan Mao Ann C. McKee Annie Huang Anna F. Lee Yoshiaki MATSUMOTO D Silverbush

Background: Clinical trials of anti-Aβ monoclonal antibodies in Alzheimer disease (AD) infer target engagement from Aβ positron emission tomography (PET) and/or fluid biomarkers such as cerebrospinal (CSF) Aβ42/40.However, these measure deposits indirectly incompletely.In contrast, postmortem neuropathologic assessments allow direct investigation treatment effects on brain and many other pathologic features.Methods: From a clinical trial dominantly inherited AD, we measured...

10.1093/jnen/nlae036 article EN other-oa Journal of Neuropathology & Experimental Neurology 2024-05-10

The primary mechanism for eliminating synaptically released glutamate is uptake by astrocytes. In the present study, we examined whether traumatic brain injury (TBI) affects cellular expression of transporters EAAT1 and EAAT2. Morphometrical immunohistochemical analysis demonstrated a predominant EAAT2 in astrocytes normal human neocortex (n = 10). Following 55), number EAAT2-positive cells was decreased prolonged survival period within traumatized pericontusional region. GFAP-positive first...

10.1089/neu.2006.23.1518 article EN Journal of Neurotrauma 2006-10-01

Abstract Traumatic brain injury is followed by increased extracellular glutamate concentration. Uptake of mainly mediated the glial transporters GLAST and GLT‐1. Extent distribution GLT‐1 were studied in a rat model controlled cortical impact (CCII). Western Blot analysis revealed lowest levels with decrease 40%–54% 42%–49% between 24 72 h posttrauma. By 8 after CCII, CSF (10.5 μM vs. 2.56 controls; P < 0.001), reaching maximum values 48 h. A significant increase de novo expressing...

10.1002/glia.1082 article EN Glia 2001-07-24

Abstract Rhabdoid phenotype and loss of SMARCB1 expression in a brain tumor are characteristic features atypical teratoid/rhabdoid tumors (ATRT). Rare non‐rhabdoid showing cribriform growth pattern have been designated neuroepithelial (CRINET). Small case series suggest that CRINETs may relatively favorable prognosis. However, the long‐term outcome is unclear it remains uncertain whether CRINET represents distinct entity or variant ATRT. Therefore, 10 were clinically molecularly...

10.1111/bpa.12413 article EN Brain Pathology 2016-07-06

Abstract Histological visualizations are critical to clinical disease management and fundamental biological understanding. However, current approaches that rely on bright-field microscopy require extensive tissue preparation prior imaging. These processes both labor intensive contribute creating significant delays in feedback for treatment decisions can extend 2–3 weeks standard paraffin-embedded interpretation, especially if ancillary testing is needed. Here, we present the first...

10.1038/s41598-020-76155-6 article EN cc-by Scientific Reports 2020-11-05

Abstract Atypical teratoid/rhabdoid tumor (ATRT) is an aggressive central nervous system characterized by loss of SMARCB1/INI1 protein expression and comprises three distinct molecular groups, ATRT–TYR, ATRT–MYC ATRT–SHH. ATRT–SHH represents the largest group heterogeneous with regard to age, location epigenetic profile. We, therefore, aimed investigate if heterogeneity within might also have biological clinical importance. Consensus clustering DNA methylation profiles confirmatory t-SNE...

10.1007/s00401-022-02424-5 article EN cc-by Acta Neuropathologica 2022-04-30

Glioblastoma is the most common and aggressive malignant brain tumor in adults, with an increasing incidence a poor prognosis. Current challenges glioblastoma management include rapid growth, limited treatment effectiveness, high recurrence rates, significant impact on patients’ quality of life. Given complexity care recent advancements diagnostic modalities, updated guidelines are needed Canada. This Delphi study aimed to develop Canadian consensus recommendations for diagnosis,...

10.3390/curroncol32040207 article EN cc-by Current Oncology 2025-04-01

Abstract Malignant brain tumors are among the deadliest neoplasms with lowest survival rates of any cancer type. In considering surgical tumor resection, suboptimal extent resection is linked to poor clinical outcomes and lower overall rates. Currently available tools for intraoperative histopathological assessment require an average 20 min processing limited diagnostic quality guiding surgeries. Consequently, there unaddressed need a rapid imaging technique guide maximal tumors. Working...

10.1038/s41598-020-74160-3 article EN cc-by Scientific Reports 2020-10-14

CT7 (MAGE-C1) is a member of the cancer testis (CT) antigen family. The present study describes generation CT7-33, monoclonal antibody (MAb) to CT7, and preliminary protein expression analysis in normal tissues limited number neoplastic lesions. CT7-33 was effective frozen as well formalin-fixed, paraffin-embedded tissues, immunohistochemistry/reverse transcriptase polymerase chain reaction (RT-PCR) co-typing demonstrated specificity. immunoreactivity adult restricted testicular germ cells....

10.1002/ijc.10416 article EN International Journal of Cancer 2002-05-23
Coming Soon ...